Literature DB >> 7845001

Specific thrombopoietin cloned and sequenced--with personal retrospect and clinical prospects.

E Kelemen.   

Abstract

Description of some properties, and nomination of human thrombopoietin (TP) had already occurred in Hungary, in 1958. In 1994 five laboratories (three in USA, one in France and one in Japan) independently published clonal purification, sequencing, and chromosomal localization of TP. This breakthrough now approaches therapeutic use in humans.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7845001

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  2 in total

1.  An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

Authors:  J J Cornelissen; R E Ploemacher; B W Wognum; A Borsboom; H C Kluin-Nelemans; A Hagemeijer; B Löwenberg
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

2.  Thrombopoietin upregulates nucleolin mRNA and protein in thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO.

Authors:  Takatoshi Ito; Mitsuhiro Fujihara; Atsushi Oda; Shinobu Wakamoto; Miki Yamaguchi; Norio Komatsu; Hiroshi Miyazaki; Hiroshi Azuma; Hisami Ikeda; Kenji Ikebuchi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.